promising agents under investigation for the treatment of myelofibrosis with cytopenia
Published 1 year ago • 143 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
4:48
an insight into the management of cytopenias in mf
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
1:44
momelotinib: a promising agent in mf
-
1:56
overview of the clinical management of patients with mf
-
0:47
novel agents being explored for the treatment of immune-mediated ttp
-
1:14
promising novel agents in aml: menin inhibitors
-
2:13
exciting agents and treatment approaches emerging in the field of myelofibrosis
-
2:13
the future of mpn treatment: exciting agents and targets being investigated
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
1:04
exciting updates in mf: novel targets and agents
-
2:00
novel treatment strategies in myelofibrosis
-
3:54
an insight into how novel agents are influencing survival outcomes in patients with mf
-
1:10
upcoming novel agents for the treatment of sickle cell disease
-
1:33
the need for novel therapeutic agents in myeloproliferative neoplasms
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:28
comorbidities and treatment decisions in myelofibrosis